Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00022295 | Phenoxodiol in Treating Patients With Refractory Solid Tumors | PHASE1 | COMPLETED | 36 | — | — | Aug 1, 2001 | Oct 1, 2007 | Mar 26, 2013 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| idronoxil | DRUG | - |
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumor * Refractory to standard therapy OR * No standard therapy exists * No breast cancer * No active CNS metastases * Known CNS metastases must be previously treated with radiotherapy or surgery and stable for at le...